[MK TEST DO NOT TOUCH] The 2024 American Academy of Dermatology (AAD) Annual Meeting

Pooled analyses of the phase III THRIVEAA1 and THRIVE-AA2 trials underpin the potential of the selective oral JAK* 1/2 inhibitor deuruxolitinib to effectively and safely reverse hair loss in adults with moderate-to-severe alopecia areata (AA).

Treatment with lebrikizumab in combination with topical corticosteroids (TCS), compared with TCS alone, results in early and sustained improvements in patient-reported outcomes (PROs) among individuals with moderate-to-severe atopic dermatitis (AD), as shown in a Japan study.

In the phase II dose-ranging STRIDE trial presented at AAD 2024, ESK-001, a highly-selective and potentially best-in-class allosteric tyrosine kinase 2 (TYK2) inhibitor, demonstrated favourable efficacy and safety signals for the treatment of adults with moderate-to-severe plaque psoriasis.

Individuals dealing with the stubborn scars and hyperpigmentation left behind by acne may find benefit in trifarotene cream – the newest among the new generation of topical retinoids approved for acne treatment, according to the findings of two vehicle-controlled, phase IV studies presented at AAD 2024.